{"id":12062,"date":"2021-04-20T17:47:45","date_gmt":"2021-04-20T12:17:45","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=12062"},"modified":"2021-07-24T12:58:20","modified_gmt":"2021-07-24T07:28:20","slug":"pharma-happenings-for-adagio-lyndra-bms-anixa","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-adagio-lyndra-bms-anixa","title":{"rendered":"Adagio Raises $336 M; Lyndra&#8217;s Schizo Trial; BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a10aaedc2562\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a10aaedc2562\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-adagio-lyndra-bms-anixa\/#Adagio_Raises_336_Million_to_Advance_Covid-19_Antibody_Treatment\" >Adagio Raises $336 Million to Advance Covid-19 Antibody Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-adagio-lyndra-bms-anixa\/#Lyndras_Pill_Gleams_in_Schizophrenia_Phase_2_Trial\" >Lyndra&#8217;s Pill Gleams in Schizophrenia Phase 2 Trial&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-adagio-lyndra-bms-anixa\/#Bristol_Myers_Opdivo_Wins_FDA_Nod_for_Gastric_Cancer_Treatment\" >Bristol Myers&#8217; Opdivo Wins FDA Nod for Gastric Cancer Treatment&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-adagio-lyndra-bms-anixa\/#Anixa_Faces_Backlash_with_Ovarian_Cancer_CAR-T_Therapy\" >Anixa Faces Backlash with Ovarian Cancer CAR-T Therapy&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-adagio-raises-336-million-to-advance-covid-19-antibody-treatment\"><span class=\"ez-toc-section\" id=\"Adagio_Raises_336_Million_to_Advance_Covid-19_Antibody_Treatment\"><\/span><strong>Adagio Raises $336 Million to Advance Covid-19 Antibody Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>An antibody startup Adagio Therapeutics announced the completion of a $336 million Series C financing round. The proceedings from the financing round will be used to augment the development of the company\u2019s lead program developing treatments for COVID-19.&nbsp;<\/p>\n\n\n\n<p>The company is working day and night to design a monoclonal antibody agent ADG20 that can both act as a therapeutic agent as well as a preventive measure. Not long ago, Adagio launched Phase I trial of the mAb in healthy volunteers. The company is also investigating the agent in pivotal Phase I\/II\/III trial in high-risk patients with mild or moderate COVID-19 and is eyeing another trial for therapy\u2019s efficacy in preventing symptomatic <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\">COVID-19<\/a>.<\/p>\n\n\n\n<p>The round was fuelled by RA Capital Management, concurrently with new investors Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another unnamed investor from the health care space. Other investors included Fidelity Management &amp; Research Company, LLC, OrbiMed, Polaris Partners, Mithril, GV, Population Health Partners, Adimab, and Omega Funds.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lyndra-s-pill-gleams-in-schizophrenia-phase-2-trial\"><span class=\"ez-toc-section\" id=\"Lyndras_Pill_Gleams_in_Schizophrenia_Phase_2_Trial\"><\/span><strong>Lyndra&#8217;s Pill Gleams in Schizophrenia Phase 2 Trial&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Approximately 2.2 million Americans receive daily pills to keep <a href=\"https:\/\/www.delveinsight.com\/blog\/schizophrenia-market\/?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\">Schizophrenia <\/a>at bay, however, they are more likely at risk of becoming non-adherent to the medications. Further, the majority of the patient\u2019s relapse in the first five years of the treatment course, says the research.&nbsp;<\/p>\n\n\n\n<p>However, it seems Lyndra Therapeutics might have some good luck with its therapeutic agent. The company is testing its oral, once-a-week therapy, LYN-005, in patients with Schizophrenia, and the therapy has shown the potential in proffering sustained and extended levels of a commonly used medication, risperidone, an antipsychotic commonly used to treat schizophrenia and bipolar disorder.<\/p>\n\n\n\n<p>The company also ensured that the sustained levels of risperidone from a single dose managed to improve drug adherence and compliance in patients. Besides, the therapy will also offer patients the third option of weekly oral pill in comparison to available treatment options that range between either daily pills or long-acting injectables.&nbsp;&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-bristol-myers-opdivo-wins-fda-nod-for-gastric-cancer-treatment\"><span class=\"ez-toc-section\" id=\"Bristol_Myers_Opdivo_Wins_FDA_Nod_for_Gastric_Cancer_Treatment\"><\/span><strong>Bristol Myers&#8217; Opdivo Wins FDA Nod for Gastric Cancer Treatment<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The US FDA had approved the use of Bristol Myers Squibb\u2019s Opdivo for previously untreated <a href=\"https:\/\/www.delveinsight.com\/report-store\/gastric-cancer-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\">gastric cancer<\/a>, gastroesophageal junction cancer and esophageal adenocarcinoma that are advanced or spread to other parts of the body, to be used in conjunction with chemotherapy.&nbsp;<\/p>\n\n\n\n<p>As per the results from the Checkmate-649 trial, the company says, Opdivo is the first and only immunotherapy, which in tandem with chemotherapy, has delivered superior overall survival versus chemotherapy alone in first-line metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. The approval of the therapy is for all the tumors regardless of their expression of the PD-L1 marker.<\/p>\n\n\n\n<p>Stomach cancers are comparatively harder to treat, and the approval marks the launch of the first treatment to extend survival benefit. However, there are risks of some serious side effects such as serious immune-mediated side effects, including inflammation of healthy organs and other common side effects in combination with chemotherapy include peripheral neuropathy (damage to the nerves outside of the brain and spinal cord), nausea, fatigue, diarrhea, vomiting, decreased appetite, abdominal pain, constipation and musculoskeletal pain.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-anixa-faces-backlash-with-ovarian-cancer-car-t-therapy\"><span class=\"ez-toc-section\" id=\"Anixa_Faces_Backlash_with_Ovarian_Cancer_CAR-T_Therapy\"><\/span><strong>Anixa Faces Backlash with Ovarian Cancer CAR-T Therapy&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Anixa is running clinical trials of its Chimeric Antigen Receptor-T cell therapy (CAR-T) in collaboration with the Moffitt Cancer Center (MCC) for <a href=\"https:\/\/www.delveinsight.com\/blog\/ovarian-cancer-market\/?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\">Ovarian cancer<\/a>. Not less than a month ago, the company had submitted an Investigational New Drug (IND) application for the same.&nbsp;<\/p>\n\n\n\n<p>However, the regulatory agency is demanding more information before approving a clinical study on CAR-T cell therapy and the companies anticipate guidance from the agency on moving forward.&nbsp;<\/p>\n\n\n\n<p>At the moment, the US FDA has approved five CAR-T therapies for different types of lymphoma and multiple myeloma with over 600 open, active clinical trials. Recently, BMS and bluebird bio won approval for its CAR-T therapy for <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\">multiple myeloma<\/a> treatment. The company also homes an approved CAR-T cell therapy, Ide-cel, marketed under Abecma and Breyanzi.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Adagio Raises $336 Million to Advance Covid-19 Antibody Treatment An antibody startup Adagio Therapeutics announced the completion of a $336 million Series C financing round. The proceedings from the financing round will be used to augment the development of the company\u2019s lead program developing treatments for COVID-19.&nbsp; The company is working day and night to [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":12066,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[12288,16958,410],"industry":[17225],"therapeutic_areas":[17239,17228],"class_list":["post-12062","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-car-t-cell-therapy-market","tag-gastric-cancer","tag-multiple-myeloma","industry-pharmaceutical","therapeutic_areas-gastroenterology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy<\/title>\n<meta name=\"description\" content=\"Adagio Raises $336 M for COVID therapy; Lyndra&#039;s Schizo Trial; BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-adagio-lyndra-bms-anixa\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy\" \/>\n<meta property=\"og:description\" content=\"Adagio Raises $336 M for COVID therapy; Lyndra&#039;s Schizo Trial; BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-adagio-lyndra-bms-anixa\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-20T12:17:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/20174602\/recent-biotech-pharma-lifescience-industry-news-updates-for-adagio-lyndra-bms-anixa.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy","description":"Adagio Raises $336 M for COVID therapy; Lyndra's Schizo Trial; BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-adagio-lyndra-bms-anixa","og_locale":"en_US","og_type":"article","og_title":"BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy","og_description":"Adagio Raises $336 M for COVID therapy; Lyndra's Schizo Trial; BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-adagio-lyndra-bms-anixa","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-04-20T12:17:45+00:00","article_modified_time":"2021-07-24T07:28:20+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/20174602\/recent-biotech-pharma-lifescience-industry-news-updates-for-adagio-lyndra-bms-anixa.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-adagio-lyndra-bms-anixa","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-adagio-lyndra-bms-anixa","name":"BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-adagio-lyndra-bms-anixa#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-adagio-lyndra-bms-anixa#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/20174602\/recent-biotech-pharma-lifescience-industry-news-updates-for-adagio-lyndra-bms-anixa.jpg","datePublished":"2021-04-20T12:17:45+00:00","dateModified":"2021-07-24T07:28:20+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Adagio Raises $336 M for COVID therapy; Lyndra's Schizo Trial; BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-adagio-lyndra-bms-anixa"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-adagio-lyndra-bms-anixa#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/20174602\/recent-biotech-pharma-lifescience-industry-news-updates-for-adagio-lyndra-bms-anixa.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/20174602\/recent-biotech-pharma-lifescience-industry-news-updates-for-adagio-lyndra-bms-anixa.jpg","width":772,"height":482,"caption":"recent-biotech-pharma-lifescience-industry-news-updates-for-adagio-lyndra-bms-anixa"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/20174602\/recent-biotech-pharma-lifescience-industry-news-updates-for-adagio-lyndra-bms-anixa-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CAR-T cell therapy market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gastric cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Multiple Myeloma<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">CAR-T cell therapy market<\/span>","<span class=\"advgb-post-tax-term\">Gastric cancer<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Apr 20, 2021","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Apr 20, 2021 5:47 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"recent-biotech-pharma-lifescience-industry-news-updates-for-adagio-lyndra-bms-anixa","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12062","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=12062"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12062\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/12066"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=12062"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=12062"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=12062"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=12062"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=12062"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}